Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research

Pancreatic ductal adenocarcinoma is an aggressive cancer with high recurrence rates following surgical resection. While adjuvant chemotherapy improves survival, a significant proportion of patients are unable to initiate or complete all intended therapy following pancreatectomy due to postoperative...

Descripción completa

Detalles Bibliográficos
Autores principales: Cloyd, Jordan M, Tsung, Allan, Hays, John, Wills, Celia E, Bridges, John FP
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Opinion Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002907/
https://www.ncbi.nlm.nih.gov/pubmed/32063686
http://dx.doi.org/10.3748/wjg.v26.i4.375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002907/
https://www.ncbi.nlm.nih.gov/pubmed/32063686
http://dx.doi.org/10.3748/wjg.v26.i4.375

Ejemplares similares